Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.

by Swee Lin G Chen Yi Mei, Alexander J Thompson, Britt Christensen, Georgina Cunningham, Lucy McDonald, Sally Bell, David Iser, Tin Nguyen, Paul V Desmond
Published 2017-01-01

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study

by Marianne Martinello, Sanjay Bhagani, David Shaw, Chloe Orkin, Graham Cooke, Edward Gane, David Iser, Andrew Ustianowski, Ranjababu Kulasegaram, Catherine Stedman, Elise Tu, Jason Grebely, Gregory J. Dore, Mark Nelson, Gail V. Matthews
Published 2023-10-01

High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study

by Jasmine Yee, Joanne M. Carson, Behzad Hajarizadeh, Joshua Hanson, James O’Beirne, David Iser, Phillip Read, Anne Balcomb, Joseph S. Doyle, Jane Davies, Marianne Martinello, Philiipa Marks, Gregory J. Dore, Gail V. Matthews, the REACH‐C Study Group
Published 2022-03-01

Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.

by Timothy Papaluca, Anne Craigie, Lucy McDonald, Amy Edwards, Michael MacIsaac, Jacinta A Holmes, Matthew Jarman, Tanya Lee, Hannah Huang, Andrew Chan, Mark Lai, Vijaya Sundararajan, Joseph S Doyle, Margaret Hellard, Mark Stoove, Jessica Howell, Paul Desmond, David Iser, Alexander J Thompson
Published 2020-01-01

Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C

by Timothy Papaluca, Anne Craigie, Lucy McDonald, Amy Edwards, Michael MacIsaac, Jacinta A. Holmes, Matthew Jarman, Tanya Lee, Hannah Huang, Andrew Chan, Mark Lai, Vijaya Sundararajan, Joseph S. Doyle, Margaret Hellard, Mark Stoove, Jessica Howell, Paul Desmond, David Iser, Alexander J. Thompson, Chen-Hua Liu
Published 2020-01-01